The oral treatment is taken within five days of symptom onset and has been shown in a pre-Omicron trial to reduce COVID hospitalisations and deaths by 30% among at-risk people.
WASHINGTON: Merck's anti-Covid pill remains "active" against the Omicron variant, the US drugmaker said Friday (Jan 28), citing results from six laboratory studies.